JP2005535285A - 分子肝毒性モデリング - Google Patents

分子肝毒性モデリング Download PDF

Info

Publication number
JP2005535285A
JP2005535285A JP2003564220A JP2003564220A JP2005535285A JP 2005535285 A JP2005535285 A JP 2005535285A JP 2003564220 A JP2003564220 A JP 2003564220A JP 2003564220 A JP2003564220 A JP 2003564220A JP 2005535285 A JP2005535285 A JP 2005535285A
Authority
JP
Japan
Prior art keywords
genes
gene
liver
expression level
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535285A5 (enExample
Inventor
ドナ メンドリック，
マーク ポーター，
コリー ジョンソン，
ブランドン ヒッグス，
アーサー カストル，
ミカエル エラショフ，
Original Assignee
ジーン ロジック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーン ロジック インコーポレイテッド filed Critical ジーン ロジック インコーポレイテッド
Publication of JP2005535285A publication Critical patent/JP2005535285A/ja
Publication of JP2005535285A5 publication Critical patent/JP2005535285A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2003564220A 2002-01-31 2003-01-31 分子肝毒性モデリング Pending JP2005535285A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6008702A 2002-01-31 2002-01-31
US36405502P 2002-03-15 2002-03-15
US36404502P 2002-03-15 2002-03-15
US43664302P 2002-12-30 2002-12-30
PCT/US2003/003194 WO2003064624A2 (en) 2002-01-31 2003-01-31 Molecular hepatotoxicology modeling

Publications (2)

Publication Number Publication Date
JP2005535285A true JP2005535285A (ja) 2005-11-24
JP2005535285A5 JP2005535285A5 (enExample) 2006-03-16

Family

ID=27670970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564220A Pending JP2005535285A (ja) 2002-01-31 2003-01-31 分子肝毒性モデリング

Country Status (6)

Country Link
US (1) US20070027634A1 (enExample)
EP (1) EP1476747A4 (enExample)
JP (1) JP2005535285A (enExample)
AU (1) AU2003214981A1 (enExample)
CA (1) CA2471661A1 (enExample)
WO (1) WO2003064624A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031375A (ja) * 2011-07-29 2013-02-14 Medichrome:Kk 遺伝子発現変動解析による化学物質の毒性評価方法
JP2016104032A (ja) * 2016-02-23 2016-06-09 株式会社メディクローム 化学物質の生体毒性の評価方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
WO2003025122A2 (en) * 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
WO2005014793A2 (en) * 2003-08-07 2005-02-17 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US8131473B1 (en) * 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
KR100565698B1 (ko) * 2004-12-29 2006-03-28 디지탈 지노믹스(주) 급성골수성백혈병(aml), b-세포형 급성임파구성백혈병(b-all), t 세포형 급성임파구성백혈병(t-all) 진단용 마커
WO2006107846A2 (en) * 2005-04-01 2006-10-12 University Of Florida Research Foundation, Inc. Biomakers of liver injury
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US10957217B2 (en) 2006-08-25 2021-03-23 Ronald A. Weitzman Population-sample regression in the estimation of population proportions
US11151895B2 (en) * 2006-08-25 2021-10-19 Ronald Weitzman Population-sample regression in the estimation of population proportions
JP5781436B2 (ja) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
EP2264454A1 (en) * 2009-06-11 2010-12-22 Universiteit Maastricht Method for screening compounds for preventing the adverse effects of reactive oxygen species on eukaryotic cells
EP2531224B1 (en) 2010-01-26 2019-06-05 Bioregency, Inc. Compositions and methods relating to argininosuccinate synthetase
US10191033B2 (en) 2013-12-05 2019-01-29 The Broad Institute, Inc. Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN110366558A (zh) 2016-10-28 2019-10-22 班扬生物标记公司 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3509100B2 (ja) * 1993-01-21 2004-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 哺乳動物のストレスプロモーターを利用する化合物の毒性測定方法および診断用キット
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
EP0935784A2 (en) * 1996-11-04 1999-08-18 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
AU9200398A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in granulocytic cells
EP1032663A1 (en) * 1997-11-20 2000-09-06 Smithkline Beecham Corporation Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription
WO1999037817A1 (en) * 1998-01-26 1999-07-29 Schering Aktiengesellschaft Gene expression methods for screening compounds
US6403778B1 (en) * 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
CA2353309A1 (en) * 1998-12-09 2000-06-15 Vistagen, Inc. Toxicity typing using embryoid bodies
CA2361590C (en) * 1999-02-05 2011-03-22 Rina Das Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20010049139A1 (en) * 2000-03-23 2001-12-06 Eric Lagasse Hepatic regeneration from hematopoietic stem cells
DE60140120D1 (de) * 2000-06-14 2009-11-19 Vistagen Inc Toxizitätstypisierung unter verwendung von leberstammzellen
AU2001281322A1 (en) * 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
JP2004522411A (ja) * 2000-07-31 2004-07-29 ジーン ロジック インコーポレイテッド 分子毒性学モデリング
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US7993907B2 (en) * 2001-05-08 2011-08-09 Mowycal Lending, Llc Biochips and method of screening using drug induced gene and protein expression profiling
US7269516B2 (en) * 2001-05-15 2007-09-11 Psychogenics, Inc. Systems and methods for monitoring behavior informatics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031375A (ja) * 2011-07-29 2013-02-14 Medichrome:Kk 遺伝子発現変動解析による化学物質の毒性評価方法
JP2016104032A (ja) * 2016-02-23 2016-06-09 株式会社メディクローム 化学物質の生体毒性の評価方法

Also Published As

Publication number Publication date
WO2003064624A2 (en) 2003-08-07
EP1476747A4 (en) 2008-06-11
WO2003064624A3 (en) 2003-12-11
US20070027634A1 (en) 2007-02-01
AU2003214981A1 (en) 2003-09-02
EP1476747A2 (en) 2004-11-17
CA2471661A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
JP2005535285A (ja) 分子肝毒性モデリング
Yeh et al. Effect of contaminants of emerging concern on liver mitochondrial function in Chinook salmon
Canesi et al. Environmental effects of BPA: focus on aquatic species
Rosen et al. Gene profiling in the livers of wild-type and PPARα-null mice exposed to perfluorooctanoic acid
AU2025204996A1 (en) Method for designing rna binding protein utilizing ppr motif, and use thereof
Brausch et al. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing
Fraz et al. Paternal exposure to carbamazepine impacts zebrafish offspring reproduction over multiple generations
AU2025201794A1 (en) Detecting breast cancer
Depiereux et al. Intersex occurrence in rainbow trout (Oncorhynchus mykiss) male fry chronically exposed to ethynylestradiol
Linhart et al. Comparison of sperm velocity, motility and fertilizing ability between firstly and secondly activated spermatozoa of common carp (Cyprinus carpio)
Huang et al. New insights into the metabolism and toxicity of bisphenol A on marine fish under long-term exposure
Chang et al. Stereoselective degradation and thyroid endocrine disruption of lambda-cyhalothrin in lizards (Eremias argus) following oral exposure
Uren Webster et al. The herbicide linuron inhibits cholesterol biosynthesis and induces cellular stress responses in brown trout
AU2024220212A1 (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
Alcaraz et al. Development of a comprehensive toxicity pathway model for 17α-ethinylestradiol in early life stage fathead minnows (Pimephales promelas)
Mustapha et al. Comparative transcriptome analysis of the differentiating gonads in Scatophagus argus
Cereser et al. An evaluation of thiram toxicity on cultured human skin fibroblasts
Guo et al. Freshwater crustacean exposed to active pharmaceutical ingredients: ecotoxicological effects and mechanisms
JP2007501617A (ja) 初代ラット肝細胞毒性モデリング
Lee et al. Exposure to low concentrations of di-n-butyl phthalate during embryogenesis reduces survivability and impairs development of Xenopus laevis frogs
Meador et al. Exposure of juvenile Chinook salmon to effluent from a large urban wastewater treatment plant. Part 2. Metabolomic profiling
Atchley The effect of selection on brain and body size association in rats
Johnston et al. Tissue explant coculture model of the hypothalamic–pituitary–gonadal–liver axis of the fathead minnow (Pimephales promelas) as a predictive tool for endocrine disruption
Cahill et al. Screening for negative effects of candidate ascidian antifoulant compounds on a target aquaculture species, Perna canaliculus Gmelin
Greenlee et al. The antiestrogen ICI 182,780 abolishes developmental injury for murine embryos exposed in vitro to o, p′-DDT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060124

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519